Dynamic Technology Lab Private Ltd Purchases Shares of 9,016 10x Genomics, Inc. (NASDAQ:TXG)

Dynamic Technology Lab Private Ltd bought a new position in 10x Genomics, Inc. (NASDAQ:TXG) during the 3rd quarter, Holdings Channel.com reports. The institutional investor bought 9,016 shares of the company’s stock, valued at approximately $204,000.

Several other hedge funds have also modified their holdings of the stock. GAMMA Investing LLC raised its holdings in shares of 10x Genomics by 451.8% in the 3rd quarter. GAMMA Investing LLC now owns 1,545 shares of the company’s stock worth $35,000 after purchasing an additional 1,265 shares during the period. Capital Performance Advisors LLP acquired a new stake in shares of 10x Genomics in the third quarter worth $35,000. Allspring Global Investments Holdings LLC raised its stake in shares of 10x Genomics by 134.5% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,637 shares of the company’s stock valued at $32,000 after acquiring an additional 939 shares during the period. Blue Trust Inc. lifted its holdings in shares of 10x Genomics by 136.5% during the 3rd quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock valued at $40,000 after acquiring an additional 1,025 shares in the last quarter. Finally, First Horizon Advisors Inc. boosted its position in 10x Genomics by 74.1% during the 2nd quarter. First Horizon Advisors Inc. now owns 1,898 shares of the company’s stock worth $37,000 after purchasing an additional 808 shares during the period. 84.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on TXG shares. Barclays lowered their target price on 10x Genomics from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Canaccord Genuity Group lowered their price target on shares of 10x Genomics from $32.00 to $20.00 and set a “buy” rating for the company in a report on Thursday, October 10th. Stephens reiterated an “overweight” rating and issued a $30.00 price objective on shares of 10x Genomics in a report on Thursday, October 10th. Citigroup lowered their price objective on 10x Genomics from $35.00 to $23.00 and set a “buy” rating for the company in a research note on Wednesday, October 30th. Finally, The Goldman Sachs Group decreased their price target on shares of 10x Genomics from $16.00 to $14.00 and set a “sell” rating for the company in a research report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $29.19.

10x Genomics Trading Up 3.6 %

NASDAQ TXG opened at $16.47 on Tuesday. 10x Genomics, Inc. has a 1-year low of $12.95 and a 1-year high of $57.90. The company has a market capitalization of $1.99 billion, a price-to-earnings ratio of -10.76 and a beta of 1.87. The stock’s 50 day moving average is $16.89 and its two-hundred day moving average is $19.50.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings data on Tuesday, October 29th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.04. 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. The company had revenue of $151.65 million during the quarter, compared to analysts’ expectations of $158.84 million. During the same period last year, the business earned ($0.51) earnings per share. The business’s revenue was down 1.3% on a year-over-year basis. On average, analysts predict that 10x Genomics, Inc. will post -1.4 earnings per share for the current year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.